Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Clinical trial NCT06528769 · RECRUITING
Trial details
- NCT number
- NCT06528769
- Sponsor
- Gabriel Tinoco
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-10
- Primary completion
- 2027-12-31
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.